For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Tafamidis and Attruby represents a true advancement . These novel therapies preserve the transthyretin protein, halting its destructive build-up and alleviating the severity of the co